FY25 consensus $7.32. Raises FY25 revenue view to $854M-$873M from $818M-$834M, consensus $847.99M. Raises FY25 adjusted EBITDA view to $221M-$228M from $213M-$223M.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals reports Q3 adjusted EPS $2.04, consensus $1.77
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals price target raised to $90 from $77 at Truist
- ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares
- Strong Growth Potential for ANI Pharmaceuticals Driven by Cortrophin Gel and Strategic Expansion